Randomized clinical trial: Benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease

Menopause

Volumn 23, Issue 8, 2016, Pages 876-883

  Rezende, Rosamar E F ^a   Duarte, Sebastião M B ^a   Stefano, Jose T ^a   Roschel, Hamilton ^a   Gualano, Bruno ^a   De Sá Pinto, Ana L ^a   Vezozzo, Denise C P ^a   Carrilho, Flair J ^a   Oliveira, Claudia P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aerobic physical activity; Nonalcoholic fatty liver disease; Postmenopausal women

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOKINE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN DERIVATIVE; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; HIGH DENSITY LIPOPROTEIN;

ADULT; AEROBIC EXERCISE; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASSESSMENT OF HUMANS; BODY COMPOSITION; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; ELASTOGRAPH; ELASTOGRAPHY; FAT CONTENT; FATTY LIVER; FEMALE; FUNCTIONAL STATUS; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEALTH PROGRAM; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LIVER BIOPSY; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PHYSICAL ACTIVITY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; EXERCISE; KINESIOTHERAPY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTHROPOMETRY; EXERCISE; EXERCISE THERAPY; FEMALE; HUMANS; LIPOPROTEINS, HDL; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTMENOPAUSE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84980009921     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000647     Document Type: Article

References (41)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007;25:883-889.
3. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009;50:204-210.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
5. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-1133.
6. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006;9:637-642.
7. Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health 2009;5:191-203.
8. Troseid M, Lappegard KT, Mollnes TE, Arnesen H, Seljeflot I. The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord 2009;7:579-584.
9. George AS, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
10. Irwin ML, Yasui Y, Ulrich CM, et al. Effect of exercise on total and intraabdominal body fat in postmenopausal women: a randomized controlled trial. JAMA 2003;289:323-330.
11. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
12. Duarte SMB, Faintuch J, Stefano JT, et al. Hypocaloric high-protein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NAFLD). Nutr Hosp 2014;29:94-101.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
14. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008;48:835-847.
15. de Lédinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010;7:811-823.
16. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-918.
17. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrassound Med Biol 2010;36:1825-1835.
18. Wasserman K, Whipp BJ, Koyl SN, Beaver WL. Anaerobic threshold and respiratory gas exchange during exercise. J Appl Physiol 1973;35: 236-243.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480.
20. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez- Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402-409.
21. Zelber-Sagi S, Busch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 2014;20:4382-4392.
22. Van der Heijden GJ, Wang ZJ, Chu ZD, et al. A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents. Obesity 2010;18:384-390.
23. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009;50:1105-1112.
24. Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol 2008;65:253-259.
25. Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011;31: 730-739.
26. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55:77-85.
27. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009;48:9-19.
28. Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011;54:153-159.
29. Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med 2014;44:211-221.
30. Lavie CJ, Milani RV, Verma A, O'Keefe JH. C-reactive protein and cardiovascular diseases-is it ready for primetime? Am J Med Sci 2009;338:486-492.
31. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010;103:71-83.
32. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003;3:293-298.
33. Soares FH, de Sousa MB. Different types of physical activity on inflammatory biomarkers in women with or without metabolic disorders: a systematic review. Womens Health 2013;53:298-316.
34. Lim S, Oh TJ, Koh KK. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 2015;201: 408-414.
35. Domanski JP, Park SJ, Harrison SA. Cardiovascular disease and nonalcoholic fatty liver disease. Does histologic severity matter? J Clin Gastroenterol 2012;46:427-430.
36. Stepanova M1, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646-650.
37. Sánchez-Muñoz V, Salas-Romero R, Del Villar-Morales A, Martínez- Coria E, Pegueros-Pérez A, Franco-Sánchez JG. Decrease of liver fat content by aerobic exercise or metformin therapy in overweight or obese women. Rev Invest Clin 2013;65:307-317.
38. Gulati M, Pandey DK, Arnsdorf MF, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation 2003;108:1554-1559.
39. Lee DC, Sui X, Artero EG, et al. Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: the Aerobics Center Longitudinal Study. Circulation 2011;124:2483-2490.
40. Lyerly GW, Sui X, Lavie CJ, Church TS, Hand GA, Blair SN. The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus. Mayo Clin Proc 2009;84:780-786.
41. Newton JL, Jones DE, Henderson E, et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 2008;57:807-813.